A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This multicenter, open label, dose-escalating study will evaluate the safety,
pharmacokinetics, pharmacodynamics, and efficacy of RO5503781, administered once daily (QD)
or once weekly (QW) in participants with advanced malignancies except leukemia. Participants
will receive multiple escalating oral doses in two different dosing schedules (Sch) until
disease progression or unacceptable toxicity occurs.